北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (6): 1078-1082. doi: 10.19723/j.issn.1671-167X.2021.06.012

• 论著 • 上一篇    下一篇

抗合成酶综合征合并心脏受累患者的临床及免疫学特征

罗澜1,2,邢晓燕2,肖云抒3,陈珂彦2,朱冯赟智2,张学武2,李玉慧2,()   

  1. 1.北京大学人民医院 眼科, 北京 100044
    2.北京大学人民医院 风湿免疫科, 北京 100044
    3.北京大学人民医院 病理科,北京 100044
  • 收稿日期:2021-08-05 出版日期:2021-12-18 发布日期:2021-12-13
  • 通讯作者: 李玉慧 E-mail:liyuhui84@163.com
  • 基金资助:
    国家自然科学基金(81801617);国家自然科学基金(81771678);国家自然科学基金(81971520);北京大学人民医院研究与发展基金(RDX2020-03)

Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement

LUO Lan1,2,XING Xiao-yan2,XIAO Yun-shu3,CHEN Ke-yan2,ZHU Feng-yun-zhi2,ZHANG Xue-wu2,LI Yu-hui2,()   

  1. 1. Department of Ophthalmology, Peking University People’s Hospital, Beijing 100044, China
    2. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
    3. Department of Pathology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2021-08-05 Online:2021-12-18 Published:2021-12-13
  • Contact: Yu-hui LI E-mail:liyuhui84@163.com
  • Supported by:
    National Natural Science Foundation of China(81801617);National Natural Science Foundation of China(81771678);National Natural Science Foundation of China(81971520);Research and Development Fund of Peking University People’s Hospital(RDX2020-03)

摘要:

目的:探讨抗合成酶综合征 (anti-synthetase syndrome, ASS)患者心脏受累的临床及免疫学特征。方法:回顾性分析2003年4月至2020年11月于北京大学人民医院风湿免疫科住院治疗的96例ASS患者资料,包括人口学资料、临床表现(皮疹、肌肉损害等)、合并症及实验室指标(肌酶、炎性标志物、免疫球蛋白、补体、淋巴细胞亚群、自身抗体等), 依据有无心脏受累进行分组比较。结果:ASS患者心脏受累的发生率为25.0% (24/96),心脏受累的患者主要表现为心肌肌钙蛋白升高(75.0%, 18/24)、心包积液(33.3%, 8/24)、左心室舒张功能减退(33.3%, 8/24)、瓣膜反流(33.3%, 8/24)。心脏受累组患者的发病年龄大于无心脏受累组[(54.58±10.58)岁 vs. (48.47±13.22)岁, P=0.043],关节炎的发生率低(37.5% vs. 61.1%, P=0.044)。心脏受累组患者合并急进性间质性肺炎的发生率高于无心脏受累组(54.2% vs. 30.6%, P=0.037)。实验室指标方面,ASS合并心脏受累组的C反应蛋白[13.55 (8.96, 38.35) mg/L vs. 4.60 (1.37, 17.40) mg/L, P=0.001]和乳酸脱氢酶[408.0 (255.0, 587.0) U/L vs. 259.5 (189.8, 393.8) U/L, P=0.007]水平均明显高于无心脏受累组。此外,心脏受累组出现抗Ro-52抗体阳性的患者比例明显高于无心脏受累组(91.7% vs. 69.4%, P=0.029),而合并危险因素、谷丙转氨酶、谷草转氨酶、肌酸激酶、动态红细胞沉降率、铁蛋白、免疫球蛋白G、补体C3、补体C4及T/B/NK淋巴细胞亚群等方面,两组差异无统计学意义。结论:ASS患者心脏受累常见,以心肌受损为主,合并C反应蛋白和乳酸脱氢酶升高、抗Ro-52抗体阳性的ASS患者应警惕心脏受累。

关键词: 抗合成酶综合征, 心肌炎, 肌炎, 自身抗体

Abstract:

Objective: To investigate the clinical and immunological features of cardiac involvement in patients with anti-synthetase syndrome (ASS). Methods: In the study, 96 patients diagnosed with ASS hospitalized in the Department of Rheumatology and Immunology, Peking University People’s Hospital from April 2003 to November 2020 were included. The patients were divided into two groups according to whether they were accompanied with cardiac involvement. Demographic features, clinical characteristics (Gottron’s sign/papules, muscle damage, etc.), comorbidities, laboratory indices (creatine kinase, inflammatory indicators, immunoglobulin, complement, lymphocyte subset, autoantibodies, etc.) were collected and the differences between the two groups were analyzed statistically. Results: The prevalence of cardiac involvement in the patients with ASS was 25.0% (24/96). The ASS patients complicated with cardiac involvement presented with elevated cardiac troponin I (cTnI, 75.0%, 18/24), pericardial effusion (33.3%, 8/24), reduction of left ventricular function (33.3%, 8/24) and valves regurgitation (33.3%, 8/24). The age of onset of the patients with cardiac involvement was older than that of the patients without cardiac involvement [(54.58±10.58) years vs. (48.47±13.22) years, P=0.043). Arthritis was observed less frequently in the patients with cardiac involvement than those without cardiac involvement (37.5% vs. 61.1%, P=0.044). In addition, rapidly progressive interstitial lung disease (54.2% vs. 30.6%, P=0.037) was observed more frequently in the patients with cardiac involvement than those without cardiac involvement. As compared with the ASS patients without cardiac involvement, C-reactive protein (CRP) [(13.55 (8.96, 38.35) mg/L vs. 4.60 (1.37, 17.40) mg/L, P=0.001], and lactate dehydrogenase (LDH) [408.0 (255.0, 587.0) U/L vs. 259.5 (189.8, 393.8) U/L, P=0.007] were significantly higher in the patients with cardiac involvement. Anti-Ro-52 antibody was detected more commonly in the ASS patients with cardiac involvement compared with the patients without cardiac involvement (91.7% vs. 69.4%, P=0.029). No significant differences were found in the comorbidities, alanine transaminase (ALT), aspartate transaminase (AST), creatine kinase (CK), erythrocyte sedimentation rate (ESR), ferritin (Fer), immunoglobulin G (IgG), complement 3 (C3), complement 4 (C4), lymphocyte subset between the two groups. Conclusion: Cardiac involvement is common in ASS, mainly manifested as myocardial damage. It is necessary to be aware of cardiac complications in patients with elevated CRP, elevated LDH and positive anti-Ro-52 antibody.

Key words: Anti-synthetase syndrome, Myocarditis, Myositis, Autoantibodies

中图分类号: 

  • R593.2

表1

ASS患者心脏受累的表现"

Variables Value, n (%)
Elevated cTnI 18 (75.0)
Elevated BNP 4 (16.7)
UCG
Pericardial effusion 8 (33.3)
PAH 4 (16.7)
Reduction of LV function 8 (33.3)
Valves regurgitation 8 (33.3)
Regional wall motion abnormality 1 (4.2)
ECG
QT interval prolongation 2 (8.3)
Abnormal T waves 2 (8.3)
ST-T segment changes 2 (8.3)

表2

合并心脏受累的ASS患者的临床表现和实验室特征"

Variables ASS with cardiac involvement (n=24) ASS without cardiac involvement (n=72) P value
Demographics
Female 17 (70.8) 49 (68.1) 0.799
Age at onset/years 54.58±10.58 48.47±13.22 0.043
Duration/month 12.0 (3.5, 34.5) 5.5 (2.0, 15.2) 0.108
Clinical features
Fever 13 (54.2) 31 (43.1) 0.344
Mechanic’s hands 16 (66.7) 38 (52.8) 0.235
Gottron’s sign/papules 22 (91.7) 52 (72.2) 0.050
Heliotrope rash 8 (33.3) 14 (19.4) 0.161
V-neck sign 5 (20.8) 14 (19.4) >0.999
Shawl sign 3 (12.5) 4 (5.6) 0.497
Myalgia 9 (37.5) 39 (54.2) 0.157
Muscle weakness 14 (58.3) 40 (55.6) 0.812
Raynaud’s phenomenon 2 (8.3) 10 (13.9) 0.722
Arthritis 9 (37.5) 44 (61.1) 0.044
Complications
ILD 24 (100.0) 68 (94.4) 0.569
RP-ILD 13 (54.2) 22 (30.6) 0.037
C-ILD 11 (45.8) 46 (63.9) 0.119
Malignancy 1 (4.2) 5 (6.9) >0.999
PAH 4 (16.7) 7 (9.7) 0.579
Venous thrombosis 3 (12.5) 3 (4.2) 0.163
Risk factors
BMIa≥24 kg/m2 14 (60.9) 35 (51.5) 0.434
Cigarette 4 (16.7) 13 (18.1) >0.999
Hypertension 11 (45.8) 19 (26.4) 0.075
Diabetes 5 (20.8) 14 (19.4) >0.999
Hyperlipidemia 5 (20.8) 14 (19.4) >0.999
Laboratory features
ALT/(U/L) 40.0 (18.2, 78.0) 29.0 (18.2, 48.0) 0.383
AST/(U/L) 46.5 (20.0, 95.5) 29.5 (20.0, 45.8) 0.129
CKb /(U/L) 642 (62, 2 167) 138 (44, 661) 0.057
LDHb/(U/L) 408.0 (255.0, 587.0) 259.5 (189.8, 393.8) 0.007
ESR/(mm/h) 29.3 (17.0, 52.2) 21.0 (8.0, 39.0) 0.074
CRPc/(mg/L) 13.55 (8.96, 38.35) 4.60 (1.37, 17.40) 0.001
Ferritind/(μg/L) 172.6 (56.1, 692.7) 183.6 (66.5, 331.2) 0.837
IgGe/(g/L) 16.9 (12.3, 22.9) 14.9 (11.6, 17.1) 0.108
C3f/(g/L) 0.97±0.26 0.98±0.25 0.819
C4f/(g/L) 0.21 (0.15, 0.24) 0.21 (0.17, 0.27) 0.329
T cellg/(cells/μL) 728 (530, 1 078) 976 (559, 1 548) 0.209
CD4+T cellg/(cells/μL) 435 (212, 619) 521 (376, 834) 0.388
CD8+T cellg/(cells/μL) 269 (200, 305) 392 (210, 545) 0.233
NK cellg/(cells/μL) 145 (86, 389) 154 (76, 391) 0.950
T cellh/% 67.01±15.31 66.51±13.42 0.888
CD4+T cellh/% 38.18±17.08 38.59±10.88 0.918
CD8+T cellh/% 24.4 (18.8, 32.0) 24.1 (18.4, 33.4) 0.987
NK cellg/% 12.7 (10.6, 29.4) 12.6 (7.1, 18.0) 0.470
CD4+/CD8+h 1.45 (1.09, 2.43) 1.56 (0.95, 2.49) 0.853

表3

合并或不合并心脏受累的两组ASS患者血清学标志物比较"

Variables ASS with cardiac involvement (n=24), n(%) ASS without cardiac involvement (n=72), n(%) P value
Anti-Jo-1 positivity 11 (45.8) 42 (58.3) 0.286
Anti-PL-7 positivity 3 (12.5) 13 (18.1) 0.752
Anti-PL-12 positivity 4 (16.7) 10 (13.9) >0.999
Anti-EJ positivity 6 (25.0) 7 (9.7) 0.121
Anti-OJ positivity 0 (0) 5 (6.9) 0.327
Anti-KS positivity 1 (4.2) 0 (0) 0.250
ANA positivity 21 (87.5) 55 (76.4) 0.246
Anti-Ro-52 positivity 22 (91.7) 50 (69.4) 0.029
[1] Jayakumar D, Zhang R, Wasserman A, et al. Cardiac manifestations in idiopathic inflammatory myopathies: An overview[J]. Cardiol Rev, 2019, 27(3):131-137.
doi: 10.1097/CRD.0000000000000241 pmid: 30585794
[2] Opinc AH, Makowski MA, Lukasik ZM, et al. Cardiovascular complications in patients with idiopathic inflammatory myopathies: Does heart matter in idiopathic inflammatory myopathies?[J]. Heart Fail Rev, 2021, 26(1):111-125.
doi: 10.1007/s10741-019-09909-8
[3] Sharma K, Orbai AM, Desai D, et al. Brief report: Antisynthetase syndrome-associated myocarditis[J]. J Card Fail, 2014, 20(12):939-945.
doi: 10.1016/j.cardfail.2014.07.012
[4] Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?[J]. Chest, 2010, 138(6):1464-1474.
doi: 10.1378/chest.10-0180
[5] Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: An international collaborative tool to facilitate myositis research[J]. Ann Rheum Dis, 2018, 77(1):30-39.
doi: 10.1136/annrheumdis-2017-211868 pmid: 28855174
[6] Li Y, Gao X, Li Y, et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7:363.
[7] Dieval C, Deligny C, Meyer A, et al. Myocarditis in patients with antisynthetase syndrome: Prevalence, presentation, and outcomes[J]. Medicine (Baltimore), 2015, 94(26):e798.
doi: 10.1097/MD.0000000000000798
[8] Katz A, Bena J, Chatterjee S. Antisynthetase syndrome: Prevalence of serositis in autoantibody subsets [C/OL]. 2018 ACR/ARHP Annual Meeting [2021-06-17]. https://acrabstracts.org/abstract/antisynthetase-syndrome-prevalence-of-serositis-in-autoan-tibody-subsets/.
[9] Ketlogetswe KS, Aoki J, Traill TA, et al. Severe aortic regurgitation secondary to antisynthetase syndrome[J]. Circulation, 2011, 124(3):e40-e41.
[10] Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis[J]. Curr Rheumatol Rep, 2012, 14(3):275-285.
doi: 10.1007/s11926-012-0249-3
[11] Wang H, Liu T, Cai YY, et al. Pulmonary hypertension in polymyositis[J]. Clin Rheumatol, 2015, 34(12):2105-2112.
doi: 10.1007/s10067-015-3095-7 pmid: 26468158
[12] Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature[J]. Medicine (Baltimore), 2012, 91(4):206-211.
doi: 10.1097/MD.0b013e318260977c
[13] Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012, 41(6):890-899.
doi: 10.1016/j.semarthrit.2011.09.008
[14] La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease[J]. Autoimmunity, 2006, 39(3):249-253.
pmid: 16769659
[15] Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020, 172(12):106134.
doi: 10.1016/j.rmed.2020.106134
[1] 肖云抒,朱冯赟智,罗澜,邢晓燕,李玉慧,张学武,沈丹华. 88例重叠肌炎的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53(6): 1088-1093.
[2] 张朴丽,杨红霞,张立宁,葛勇鹏,彭清林,王国春,卢昕. 血清YKL-40在诊断抗黑色素瘤分化相关基因5阳性皮肌炎合并严重肺损伤中的价值[J]. 北京大学学报(医学版), 2021, 53(6): 1055-1060.
[3] 伊文霞,魏翠洁,吴晔,包新华,熊晖,常杏芝. 长疗程利妥昔单抗治疗难治性幼年型特发性炎症性肌病3例[J]. 北京大学学报(医学版), 2021, 53(6): 1191-1195.
[4] 吴燕芳,高飞,林滇恬,陈志涵,林禾. 托法替布联合治疗抗MDA5抗体阳性的无肌病皮肌炎并发快速进展型间质性肺病5例临床分析[J]. 北京大学学报(医学版), 2021, 53(5): 1012-1016.
[5] 郑艺明,郝洪军,刘怡琳,郭晶,赵亚雯,张巍,袁云. Ro52抗体与其他肌炎抗体共阳性的相关性研究[J]. 北京大学学报(医学版), 2020, 52(6): 1088-1092.
[6] 甘雨舟,李玉慧,张丽华,马琳,何文雯,金月波,安媛,栗占国,叶华. 临床无肌病性皮肌炎与皮肌炎临床及免疫学特征比较[J]. 北京大学学报(医学版), 2020, 52(6): 1001-1008.
[7] 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报(医学版), 2020, 52(6): 1009-1013.
[8] 朱冯赟智,邢晓燕,汤晓菲,李依敏,邵苗,张学武,李玉慧,孙晓麟,何菁. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52(6): 995-1000.
[9] 杨红霞,田小兰,江薇,李文丽,刘青艳,彭清林,王国春,卢昕. 免疫介导坏死性肌病的临床和病理特征分析[J]. 北京大学学报(医学版), 2019, 51(6): 989-995.
[10] 李英妮,相晓红,赵静,李云,孙峰,王红彦,贾汝琳,胡凡磊. 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报(医学版), 2019, 51(6): 1019-1024.
[11] 徐婧,徐静,李鹤,唐杰,舒建龙,张婧,石连杰,李胜光. 皮肌炎合并IgA血管炎1例[J]. 北京大学学报(医学版), 2019, 51(6): 1173-1177.
[12] 杨伊莹,左晓霞,朱红林,刘思佳. 皮肌炎/多肌炎表观遗传学标志物的研究进展[J]. 北京大学学报(医学版), 2019, 51(2): 374-377.
[13] 王永福,刘媛. 自身抗体在肿瘤及感染性疾病发生、发展中的作用[J]. 北京大学学报(医学版), 2018, 50(6): 952-955.
[14] 余建峰, 金月波, 何菁, 安媛, 栗占国. 皮肌炎继发干燥综合征伴肺间质病变的血清人Ⅱ型肺泡细胞表面抗原变化1例[J]. 北京大学学报(医学版), 2017, 49(5): 910-914.
[15] 刘洪江, 石连杰, 胡凡磊, 姚海红, 栗占国, 贾园. 趋化因子配体19在系统性红斑狼疮中的表达及其与B细胞异常的相关性研究[J]. 北京大学学报(医学版), 2017, 49(5): 829-834.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报(医学版), 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报(医学版), 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报(医学版), 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报(医学版), 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报(医学版), 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报(医学版), 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报(医学版), 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报(医学版), 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报(医学版), 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报(医学版), 2007, 39(4): 346 -350 .